ID   U3047MG
AC   CVCL_IR79
SY   U3047-MG; U3047
DR   cancercelllines; CVCL_IR79
DR   GEO; GSM1857590
DR   GEO; GSM1857806
DR   Progenetix; CVCL_IR79
DR   Wikidata; Q54973705
RX   PubMed=25510230;
RX   PubMed=26629530;
RX   PubMed=27689322;
RX   PubMed=28122246;
WW   http://www.hgcc.se/
CC   Part of: Human Glioblastoma Cell Culture (HGCC) resource.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Brain; UBERON=UBERON_0000955.
ST   Source(s): PubMed=26629530
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 8,13
ST   D16S539: 9
ST   D18S51: 14,20
ST   D19S433: 14,15.2
ST   D21S11: 28,31
ST   D2S1338: 23
ST   D3S1358: 16,17
ST   D5S818: 12
ST   D7S820: 10
ST   D8S1179: 13
ST   FGA: 21,23
ST   TH01: 7,9.3
ST   TPOX: 8
ST   vWA: 14,19
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   66Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 05-10-23; Version: 8
//
RX   PubMed=25510230; DOI=10.1016/j.ejphar.2014.12.001;
RA   Babateen O., Jin Z., Bhandage A.K., Korol S.V., Westermark B.,
RA   Forsberg-Nilsson K., Uhrbom L., Smits A., Birnir B.;
RT   "Etomidate, propofol and diazepam potentiate GABA-evoked GABAA
RT   currents in a cell line derived from human glioblastoma.";
RL   Eur. J. Pharmacol. 748:101-107(2015).
//
RX   PubMed=26629530; DOI=10.1016/j.ebiom.2015.08.026;
RA   Xie Y., Bergstrom T., Jiang Y.-W., Johansson P., Marinescu V.D.,
RA   Lindberg N., Segerman A., Wicher G., Niklasson M., Baskaran S.,
RA   Sreedharan S., Everlien I., Kastemar M., Hermansson A., Elfineh L.,
RA   Libard S., Holland E.C., Hesselager G., Alafuzoff I., Westermark B.,
RA   Nelander S., Forsberg-Nilsson K., Uhrbom L.;
RT   "The Human Glioblastoma Cell Culture resource: validated cell models
RT   representing all molecular subtypes.";
RL   EBioMedicine 2:1351-1363(2015).
//
RX   PubMed=27689322; DOI=10.18632/oncotarget.12298;
RA   Schmidt L., Baskaran S., Johansson P., Padhan N., Matuszewski D.J.,
RA   Green L.C., Elfineh L., Wee S.-M., Haggblad M., Martens U.,
RA   Westermark B., Forsberg-Nilsson K., Uhrbom L., Claesson-Welsh L.,
RA   Andang M., Sintorn I.-M., Lundgren B., Lonnstedt I., Krona C.,
RA   Nelander S.;
RT   "Case-specific potentiation of glioblastoma drugs by pterostilbene.";
RL   Oncotarget 7:73200-73215(2016).
//
RX   PubMed=28122246; DOI=10.1016/j.celrep.2017.01.003;
RA   Jiang Y.-W., Marinescu V.D., Xie Y., Jarvius M., Maturi N.P.,
RA   Haglund C., Olofsson S., Lindberg N., Olofsson T., Leijonmarck C.,
RA   Hesselager G., Alafuzoff I., Fryknas M., Larsson R., Nelander S.,
RA   Uhrbom L.;
RT   "Glioblastoma cell malignancy and drug sensitivity are affected by the
RT   cell of origin.";
RL   Cell Rep. 18:977-990(2017).
//